Ravi Majeti, MD

Experts in acute myeloid leukemia (AML) discuss clonal hematopoiesis, early detection, and potential therapeutics. Topics include CRISPR engineering in investigating mutations, hereditary leukemia predispositions, risk stratification of clonal hematopoiesis, intervention with high-risk patients, interactions between somatic and germline variants, and the significance of early detection and targeted treatments for clonal hematopoiesis in AML patients.